When we are still embryos, proteins of the so-called “hedgehog” signaling pathway stimulate our cells to develop into different organs.
When we are adults, this pathway falls largely silent, except in certain tissues that constantly regenerate themselves, for example our skin, and the linings of our blood vessels and digestive tract.
Unfortunately, several types of cancer cells are able to reawaken this dormant pathway, causing surrounding healthy cells to produce growth factors (proteins or hormones that stimulate cell growth) that help the cancer cells proliferate and metastasize.
A potent remedy to the problem may be on its way. In a paper published in the Journal of the American Chemical Society, researchers in the laboratory of Rudi Fasan, an associate professor of chemistry at the University of Rochester, describe the development of a cyclic peptide that is able to block the activation of the pathway in live cells.
The next step will be to further optimize the peptide for increased potency, then proceed to animal trials.
The pathway is activated when a ligand (binding molecule) produced by cancer cells interacts with a receptor on the surface of healthy cells, triggering the production of growth factors. The first drug directed against this pathway was approved by the FDA in 2012, but according to Fasan, recent studies have shown that cancer cells become quickly resistant to it.
The cyclic peptide developed in Fasan’s lab blocks the ligand farther “upstream” in the pathway, utilizing a different mode of inhibition compared to the FDA-approved drug. “It is important to have different weapons against this pathway,” Fasan says, “and we have targeted a key component of it.” He adds that the compound is unlikely to develop resistance since it does not target a protein located on cancer cells.
The researchers initially designed a cyclic peptide that mimics a native protein inhibitor of the hedgehog ligand. The researchers then used bacteria to quickly produce and screen large “libraries” of variations of this peptide, from which compounds with improved activity against the cancer ligand could be isolated.
The risk, as in any chemotherapy, is that the drug candidate Fasan’s lab is developing will also inhibit the pathway in healthy skin, blood vessel, and digestive tract tissues that rely on the pathway for normal regeneration. However, the fact that a hedgehog pathway inhibitor was recently approved for use in cancer therapy holds promise that these risks are outweighed by the benefits of inhibiting cancer growth, Fasan says.
Learn more: Rochester chemists find new means to “block” cancer cell growth
The Latest on: Cancer cell growth
[google_news title=”” keyword=”cancer cell growth” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- How hormones impact ovarian cancer growthon May 12, 2024 at 3:00 am
Hormones can influence ovarian cancer growth by stimulating cell proliferation, angiogenesis (formation of new blood vessels), and metastasis. Hormonal imbalances, particularly estrogen and ...
- An Innovative New Cancer Treatment – Scientists Unveil Nanoparticle Capable of Crossing Blood-Brain Barrieron May 12, 2024 at 2:04 am
The scientists are optimistic that their method, which has shown initial promise in preclinical models, could eventually be used to treat both brain metastases and primary breast cancer tumors with a ...
- Stomach Cancer: How Can Your Mouthwash Help Spot The Early Symptoms?on May 11, 2024 at 8:49 pm
A simple 'swish-and-spit' mouthwash could detect the earliest signs of stomach cancer that strikes millions across the world. The oral rinse would pick up specific bacteria linked to gastric cancer ...
- Teenager’s cancer research, work with women in Nepal just the beginning for 18-year-oldon May 11, 2024 at 2:00 pm
This week, the 18-year-old senior at the Arkansas School for Mathematics, Sciences and the Arts will be in Los Angeles taking part in the Regeneron International Science and Engineering Fair, the ...
- Prelude Therapeutics Progresses in Cutting-Edge Cancer Treatment Developmenton May 10, 2024 at 3:00 am
Prelude Therapeutics Incorporated (Nasdaq: PRLD) recently shared its first quarter financial results. But even more newsworthy is the ongoing progress and future milestones slated for its novel ...
- Getting to know the enzymes behind cell communication—and tumor growthon May 8, 2024 at 9:10 am
In the human body, molecules known as kinases propagate signals within and between cells, relaying signals that allow cells to respond to changes in the environment. However, there are hundreds of ...
- Getting to know the enzymes behind cell communication — and tumor growthon May 7, 2024 at 5:00 pm
“The major class of tyrosine kinases is associated with growth factors. Understanding how tyrosine ... “And tyrosine kinase inhibitors are one of the major targeted cancer treatments. But cancer cells ...
- Unique atomic fingerprint of cancer cells discovered in hydrogen atomson May 7, 2024 at 6:53 am
Geologists and biologists use earth science tools to identify cancer's unique atomic markers known as fingerprints.
- Scientists Reveal Cancer's Atomic Secrets—'Whole New Layer to Medicine'on May 7, 2024 at 5:44 am
By studying these ratios in yeast and mouse liver cells, the team found that cells that were growing extremely fast, similar to cancer cells, contained a noticeably higher ratio of hydrogen to ...
- Drug shows promise for starving out cancer cellson May 6, 2024 at 6:43 am
Starving out tumor cells may be a promising therapy for treatment-resistant lung cancer, according to a new study published in Science Advances.
via Google News and Bing News